Clinical evidence: key trials and outcomes The kidney-protective potential of SGLT2 inhibitors was first identified in cardiovascular outcome trials, including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose (EMPA-REG OUTCOME) [36], Canagliflozin Cardiovascular Assessment Study (CANVAS) [37], and Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARETIMI 58) [38]
Most of what drives your hunger and fullness is happening below the level of conscious awareness, in a biochemical conversation between your digestive system and your brain that never really stops
Consulte con un profesional de la salud sobre los riesgos, las contraindicaciones y el seguimiento
They build a personalized plan for your needs to maximize efficacy and minimize side effects
Habits, Health, and Psychological Resilience Understanding how habits sustain or erode well-beingconsidering anhedonia, creative rest, and the restoration of mental balance in demanding professional and personal contexts
Can I get pregnant after stopping spironolactone